Hanmi Pharm (128940) financial statements
- FY2025 revenue
- ₩1.5T▲ +3.5%
- FY2025 net income
- ₩169.6B▲ +39.8%
- FY2025 diluted EPS
- ₩13,362.00▲ +39.7%
- FY2025 free cash flow
- ₩130.0B▼ −15.7%
Hanmi Pharm income statement
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 1,547,531 | 1,495,502 | 1,490,887 |
| Gross profit | 884,407 | 817,037 | 829,249 |
| Operating income | 257,799 | 216,186 | 220,691 |
| Pretax income | 213,478 | 171,254 | 193,967 |
| Net income | 169,554 | 121,315 | 146,231 |
| Diluted earnings per share | 13,362.00 | 9,567.00 | 11,522.00 |
Hanmi Pharm balance sheet
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 108,274 | 192,278 | 54,980 |
| Total assets | 2,137,598 | 2,020,840 | 1,898,668 |
| Total liabilities | 714,744 | 780,089 | 798,458 |
| Total equity | 1,422,853 | 1,240,752 | 1,100,211 |
| Long-term debt | n/a | 85,862 | 0 |
Hanmi Pharm cash flow statement
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 173,072 | 193,487 | 216,538 |
| Capital expenditure | -43,025 | -39,261 | -27,352 |
| Free cash flow (derived) | 130,048 | 154,226 | 189,186 |
| Dividends paid | -30,855 | -12,555 | -17,996 |
Quarterly highlights
| KRW millions | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 | 30 Sep 2025 |
| Revenue (derived) | 467,247 | 392,926 | 432,960 | 362,345 |
| Operating income (derived) | 131,093 | 53,649 | 83,272 | 55,069 |
| Net income (derived) | 83,310 | 45,490 | 48,116 | 40,128 |
| Diluted earnings per share | 6,566.00 | 3,586.00 | n/a | 3,165.00 |
| Operating cash flow (derived) | 104,723 | 111,641 | 14,509 | 42,023 |
| Total assets | 2,333,714 | 2,226,217 | 2,137,598 | 2,040,480 |
Hanmi Pharm major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| 한미사이언스 | 49.6% | 6,348,167 | 28 September 2026 |
| 국민연금공단 | 9.6% | 1,230,775 | 1 October 2026 |
Hanmi Pharm DART filings
| Filed | Form | Type |
|---|---|---|
| 13 August 2026 | Semiannual Report | Half-year report |
| 27 July 2026 | Major Matters Report | Current report |
| 14 May 2026 | Quarterly Report | Quarterly report |
| 19 March 2026 | Business Report | Annual report |
| 8 January 2026 | Major Matters Report | Current report |
| 13 November 2025 | Quarterly Report | Quarterly report |
| 13 August 2025 | Semiannual Report | Half-year report |
| 14 May 2025 | Quarterly Report | Quarterly report |
Common questions
What was Hanmi Pharm's revenue in fiscal 2025?
Hanmi Pharm reported ₩1.5 trillion in revenue for fiscal 2025, the year ended 31 December 2025, up 3.5% from fiscal 2024.
What was Hanmi Pharm's net income in fiscal 2025?
Hanmi Pharm reported net income of ₩169.6 billion for fiscal 2025, the year ended 31 December 2025, up 39.8% from fiscal 2024. Diluted earnings per share were ₩13,362.00.
What was Hanmi Pharm's free cash flow in fiscal 2025?
Hanmi Pharm had ₩130.0 billion in free cash flow in fiscal 2025. Operating cash flow was ₩173.1 billion and capital expenditure was ₩43.0 billion.
What were Hanmi Pharm's total assets at the end of fiscal 2025?
Hanmi Pharm reported total assets of ₩2.1 trillion at the end of fiscal 2025, the year ended 31 December 2025.
How much Hanmi Pharm history does each plan include?
Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.
Get these figures through the API
5,000 free requests every month. No card needed.